Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre,... by Yang, Yunpeng, Prof, Qu, Song, Prof, Li, Jingao, Prof, Hu, Chaosu, Prof, Xu, Mingjun, Prof, Li, Weidong, Prof, Zhou, Ting, MD, Shen, Liangfang, Prof, Wu, Hui, Prof, Lang, Jinyi, Prof, Hu, Guangyuan, Prof, Luo, Zhanxiong, Prof, Fu, Zhichao, Prof, Qu, Shenhong, Prof, Feng, Weineng, Prof, Chen, Xiaozhong, Prof, Lin, Shaojun, Prof, Zhang, Weimin, Prof, Li, Xiaojiang, Prof, Sun, Yan, Prof, Lin, Zhixiong, Prof, Lin, Qin, Prof, Lei, Feng, Prof, Long, Jianting, Prof, Hong, Jinsheng, Prof, Huang, Xiaoming, Prof, Zeng, Lingzhi, Prof, Wang, Peiguo, Prof, He, Xiaohui, Prof, Zhang, Ben, MS, Yang, Qing, MD, Zhang, Xiaojing, MD, Zou, Jianjun, MD, Fang, Wenfeng, Prof, Zhang, Li, Prof

Get full text

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial by Zhang, Li, Prof, Huang, Yan, MD, Hong, Shaodong, MD, Yang, Yunpeng, MD, Yu, Gengsheng, MD, Jia, Jun, MD, Peng, Peijian, MD, Wu, Xuan, MD, Lin, Qing, Prof, Xi, Xuping, Prof, Peng, Jiewen, MD, Xu, Mingjun, MD, Chen, Dongping, Prof, Lu, Xiaojun, MD, Wang, Rensheng, MD, Cao, Xiaolong, MD, Chen, Xiaozhong, MD, Lin, Zhixiong, Prof, Xiong, Jianping, MD, Lin, Qin, MD, Xie, Conghua, MD, Li, Zhihua, MD, Pan, Jianji, Prof, Li, Jingao, MD, Wu, Shixiu, Prof, Lian, Yingni, MD, Yang, Quanlie, MD, Zhao, Chong, Prof

Get full text